Forus vs TailorMed
Both work the gap between a prescription being written and a patient actually taking the medicine, and they are funded differently. Forus automates the paperwork, generating and submitting the prior authorisation, drafting appeals and routing to pharmacy, free to the prescriber. TailorMed finds the money, identifying financially at risk patients and matching them to assistance programmes, sold to providers and pharmacies. Both are legitimate and they are not substitutes. The question to settle first is who pays for the free one, because a platform that routes prescriptions has an economic relationship somewhere in the chain, and neither vendor publishes what the patient is told about who is contacting them.
- It automates the paperwork path from prescription to pharmacy, generating and submitting authorisations, drafting appeals and finding affordability programmes, at no cost to the prescriber.
- Coverage is stated as any drug, any insurance, any pharmacy, embedded at the point of prescribing.
- It states plainly that protected health information is covered under a business associate agreement, alongside a typed attestation.
- It identifies financially at risk patients across a large network of assistance programmes, which is provider side work aimed at what the patient can pay.
- The buyer is the health system or pharmacy, so the incentive is the patient completing therapy affordably rather than a specific therapy being dispensed.
- Financial navigation reaches across therapies and payers rather than following one prescription.
Side by Side
| Axis | F Forus |
T TailorMed |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the RCM & Prior Auth AI page.
The funding question is the whole comparison on one side: a platform free to the provider is paid for by someone else, and in medication access that is usually a manufacturer or pharmacy channel, so establish who funds it and what data flows back, because a platform routing prescriptions has an interest in where they land.
Neither vendor publishes what the patient is told at first contact, which matters because a patient often cannot tell whether the person helping them works for their clinic or for a drug company. Neither publishes subgroup performance.